Signal transduction of ischemic preconditioning

Cardiovascular Research

Volumn 52, Issue 2, 2001, Pages 181-198

  Schulz, Rainer ^a   Cohen, Michael V ^b   Behrends, Matthias ^a   Downey, James M ^b   Heusch, Gerd ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Ischemia; Preconditioning; Signal transduction

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN; ARACHIDONATE 12 LIPOXYGENASE; BRADYKININ; BRADYKININ B2 RECEPTOR; CALCIUM ION; ENDOTHELIN; ENDOTHELIN RECEPTOR AGONIST; FREE RADICAL; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; LIPOXYGENASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; NALOXONE; NITRIC OXIDE; NORADRENALIN; OPIATE RECEPTOR; PHOSPHOLIPASE C; PHOSPHOLIPASE D; POTASSIUM CHANNEL; PROSTAGLANDIN; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SIGMA OPIATE RECEPTOR; SYNAPTOPHYSIN;

CYTOSKELETON; DOG; ENZYME METABOLISM; HEART ARRHYTHMIA; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; MITOCHONDRIAL RESPIRATION; NONHUMAN; OSMOLARITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTON SODIUM EXCHANGE; RABBIT; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; STIMULUS RESPONSE; SWINE;

ADENOSINE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRADYKININ; FREE RADICALS; HUMANS; ISCHEMIC PRECONDITIONING; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; NARCOTICS; NEUROTRANSMITTER AGENTS; PROSTAGLANDINS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TIME FACTORS;

EID: 0034772136     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00384-4     Document Type: Review

References (291)

1. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium
2. Hypoxia preconditions rabbit myocardium via adenosine and catecholamine release
3. Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning
4. + channels
5. The ability of heat stress and metabolic preconditioning to protect primary rat cardiac myocytes
6. Stretch preconditions canine myocardium
7. Stretch-induced protection shares a common mechanism with ischemic preconditioning in rabbit heart
8. Ischaemic preconditioning: Present position and future directions
9. ATP channel
10. The preconditioning phenomenon. A tool for the scientist or a clinical reality?
11. Ischemic preconditioning decreases apoptosis in rat hearts in vivo
12. Ischemic preconditioning attenuates apoptotic cell death associated with ischemia/reperfusion
13. Preconditioning decreases Bax expression, PMN accumulation and apoptosis in reperfused rat heart
14. Myocardial stunning in dogs: Preconditioning effect and influence of coronary collateral flow
15. Preconditioning improves energy metabolism during reperfusion but does not attenuate myocardial stunning in porcine hearts
16. Ischaemic preconditioning in a model of global ischaemia: Infarct size limitation, but no reduction of stunning
17. Failure of preconditioning to improve postcardioplegia stunning of minimally infarcted hearts
18. Ischemic preconditioning does not acutely improve load-insensitive parameters of contractility in an in vivo stunned porcine myocardium
19. Smaller infarct after preconditioning does not predict extent of early functional improvement of reperfused heart
20. Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts
21. Reperfusion arrhythmias in the murine heart: Their characteristics and alteration after ischemic preconditioning
22. Preconditioning of ischemic myocardium: Reperfusion-induced arrhythmias
23. Effect of preconditioning ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat
24. κ- but not δ-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats
25. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning
26. Time course of the protection against ischaemia and reperfusion-induced ventricular arrhythmias resulting from brief periods of cardiac pacing
27. Preconditioning reduces infarct size but accelerates time to ventricular fibrillation in ischemic pig heart
28. Electrophysiogical characteristics of repetitive ischemic preconditioning in the pig heart
29. + ATP channels
30. Proarrhythmic effects of ischemic preconditioning in anesthetized pigs
31. The natural history of preconditioning: Cardioprotection depends on duration of transient ischemia and time to subsequent ischemia
32. Ischemic preconditioning in pigs: A graded phenomenon. Its relation to adenosine and bradykinin
33. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease
34. Ischemic preconditioning. Difference in protection and susceptibility to blockade with single-cycle versus multicycle transient ischemia
35. Myocardial protection with preconditioning
36. Ischaemic preconditioning by partial occlusion without intermittent reperfusion
37. Intraischemic preconditioning. Increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia without intermittent reperfusion
38. The influence of the time period between preconditioning ischemia and prolonged ischemia on myocardial protection
39. Ischaemic preconditioning - Time course of renewal in the pig
40. Myocardial protection is lost before contractile function recovers from ischemic preconditioning
41. Acadesine extends the window of protection afford by ischaemic preconditioning in conscious rabbits
42. The protection of ischaemic preconditioning can be reinstated in the rabbit heart after the initial protection has waned
43. Duration and renewal of myocardial protection against infarction by ischemic preconditioning in dogs
44. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart
45. Effects of preconditioning on myocardial interstitial levels of ATP and its catabolites during regional ischemia and reperfusion in the rat
46. Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size
47. Adenosine and bradykinin: Are they independent triggers of preconditioning?
48. Preconditioning-induced attenuation of purine metabolite accumulation during ischemia: Memory and multiple cycles
49. ATP channel opener: Effects on interstitial adenosine in dogs
50. Involvement of endogenous adenosine in ischaemic preconditioning in swine
51. Dynamics of myocardial metabolism in the preconditioned porcine heart studied using continuous microdialysis
52. Effects of ischemia, preconditioning and adenosine deaminase inhibition on interstitial adenosine levels and infarct size
53. Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction
54. Evidence that adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart
55. Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits
56. Adenosine-enhanced ischemic preconditioning: Adenosine receptor involvement during ischemia and reperfusion
57. Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs
58. Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: Evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection
59. Role of bradykinin in myocardial preconditioning
60. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts
61. Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning
62. Evidence for involvement of opioid receptors in ischemic preconditioning in rat hearts
63. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart
64. Opioid-induced second window of cardioprotection
65. Opioid receptor contributes to ischemic preconditioning through protein kinase C activation in rabbits
66. Naloxone blockade of myocardial ischemic preconditioning does not require central nervous system participation
67. Role of endogenous opioids in ischemic preconditioning but not in short-term hibernation in pigs
68. Ischemic preconditioning in the intact rat heart is mediated by δ1- but not μ- or κ-opioid receptors
69. Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: Implications for ischemic preconditioning
70. Anti-preconditioning
71. Fentanyl protects the heart against ischaemic injury via opioid receptors, adenosine A1 receptors and KATP channel linked mechanisms in rats
72. The cardioprotective effects of ischemic 'preconditioning' are not mediated by adenosine receptors in rat hearts
73. Cardioprotective effects of ischaemic preconditioning are not mediated by prostanoids
74. Cyclooxygenase products are not involved in protection against myocardial infarction afforded by preconditioning in rabbit. Cyclooxygenase pathway's involvement in preconditioning
75. Lipoxygenase metabolism of arachidonic acid in ischemic preconditioning and PKC-induced protection in heart
76. Leukocyte-type 12-lipoxygenase-deficient mice show impaired ischemic preconditioning-induced cardioprotection
77. Ischemic preconditioning is protein kinase C dependent but not through stimulation of α adrenergic or adenosine receptors in the isolated rat heart
78. α1-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C
79. No evidence for mediation of ischemic preconditioning by alpha1-adrenergic signal transduction pathway or protein kinase C in isolated rat heart
80. Roles of tyrosine kinase and protein kinase C in infarct size limitation by repetitive ischemic preconditioning in the rat
81. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts
82. Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit heart
83. Myocardial ischemia decreases oxidative phosphorylation through cytochrome oxidase in subsarcolemmal mitochondria
84. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes
85. The role of mitochondria in ischemic heart disease
86. The role of neutrophils in myocardial ischemia-reperfusion injury
87. Free radicals and tissue injury
88. + channel
89. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium
90. Reactive oxygen species function as second messenger during ischemic preconditioning of heart
91. Gαi and Gαo are target proteins of reactive oxygen species
92. Oxidative stress alters specific membrane currents in isolated cardiac myocytes
93. ATP channel by oxygen free radicals produced by xanthine oxidase reaction
94. Alterations in electrical activity and membrane current induced by intracellular oxygen-derived free radical stress in guinea pig ventricular myocytes
95. Nitric oxide: A trigger for classic preconditioning?
96. Exogenous nitric oxide can trigger a preconditioned state through a free radical mechanism, but endogenous nitric oxide is not a trigger of classical ischemic preconditioning
97. No involvement of endogenous nitric oxide in classical ischemic preconditioning in swine
98. 2+ channel blockade prevents ischemic preconditioning of human myocardium
99. No attenuation of ischaemic preconditioning by the calcium antagonist nisoldipine
100. Oxygen radicals can induce preconditioning in rabbit hearts
101. + channels, and the cGMP in the preconditioning response of the rabbit
102. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide
103. Nitric oxide, nitrates and ischaemic preconditioning
104. 3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anesthetized rat
105. Reduction of myocardial injury by the EP3 receptor agonist TEI-3356. Role of protein kinase C and of K(ATP)-channels
106. 3 receptors in the reperfused ischemic pig heart
107. Calcium preconditioning elicits strong protection against ischemic injury via protein kinase C signaling pathway
108. 2+ as a mediator of ischemic preconditioning
109. 2+ in activation of protein kinase C during ischemic preconditioning
110. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors
111. Adenosine and the anti-infarct effects of preconditioning
112. Pretreatment with pertussis toxin blocks the protective effects of preconditioning: Evidence for a G-protein mechanism
113. ATP channels
114. Exploration of possible roles of phospholipase D and protein kinase C in the mechanism of preconditioning in the myocardium
115. The regulation and cellular functions of phosphatidylcholine hydrolysis
116. Phospholipase D plays a role in ischemic preconditioning in rabbit heart
117. In vivo regulation of protein kinase C by trans-phosphorylation followed by autophosphorylation
118. Protein kinase C is regulated in vitro by three functionally distinct phosphorylations
119. Regulation of conventional protein kinase C isoenzymes by phosphoinositol-dependent kinase 1 (PDK-1)
120. Regulation of protein kinase C zeta by PI3-kinase and PDK-1
121. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C
122. ATP channels in the isolated rabbit heart
123. Localization of protein kinase C isozymes in cardiac myocytes
124. Anchoring proteins for protein kinase C: A means for isozyme selectivity
125. A selective ε-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death
126. PKCε activation induces dichotomous cardiac phenotypes and modulates PKCε-RACK interactions and RACK expression
127. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function
128. Protein kinase C-ε is responsible for the protection of preconditioning in rabbit cardiomyocytes
129. Use of functional proteomics to investigate PKCε-mediated cardioprotection: The signaling module hypothesis
130. Ischemic preconditioning induces selective translocation of protein kinase C isoforms ε and η in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity
131. Implication of protein kinase C-α, δ, and ε isoforms in ischemic preconditioning in perfused rat hearts
132. Role of protein kinase C-α in activation of Ecto-5′-nucleotidase in the preconditioned canine myocardium
133. Preconditioning protects ischemic rabbit heart by protein kinase C activation
134. Chelerythrine, a highly selective protein kinase C inhibitor, blocks the antiinfarct effect of ischemic preconditioning in rabbit hearts
135. Protection of ischemic preconditioning is dependent upon a critical timing sequence of protein kinase C activation
136. Protein kinase C. Its role in ischemic preconditioning in the rat
137. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts
138. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model?
139. Role of activation of protein kinase C in the infarct size-limiting effect of ischemic preconditioning trough activation of ecto-5′-nucleotidase
140. No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine
141. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart
142. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs
143. Protein tyrosine kinase is not involved in the infarct size-limiting effect of ischemic preconditioning in canine hearts
144. Role of p38 mitogen-activated protein kinases in preconditioning. A detrimental factor or a protective kinase?
145. Mitogen-activated protein kinases in the heart
146. Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart. Evidence for involvement of p38 MAPK
147. Phosphorylation of tyrosine 182 of p38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart
148. Ischemia induced activation of heat shock protein 27 kinases and casein kinase 2 in the preconditioned rabbit heart
149. Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs
150. Two distinct forms of MAPKAP kinase-2 in adult cardiac ventricular myocytes
151. Inhibition of the ER-kinase casade by PD98059 and UO126 counteracts ischemic preconditioning in pig myocardium
152. Stimulation of 'stress-regulated' mitogen-activated protein kinases (stress-activated protein kinases/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stress
153. PKC-dependent activation of p46/p54 JNKs during ischemic preconditioning in conscious rabbits
154. ATP channels and actin cytoskeleton
155. Okadaic acid and anisomycin are protective and stimulate the SAPK/JNK pathway
156. SAPKs regulation of ischemic preconditioning
157. The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes
158. Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family
159. Regulation of c-jun gene expression in endothelial cells by the protein kinase inhibitor staurosporine
160. Ischemic preconditioning triggers tyrosine kinase signaling: A potential role for MAPKAP kinase 2
161. Delayed cardioprotection of aged rat myocytes is associated with activation of mitogen-activated protein kinase
162. Tissue-specific pattern of stress kinase activation in ischemic-reperfused heart and kidney
163. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart. p38/RK mitogen-activated protein kinase are activated by ischemia/reperfusion
164. Activation of p38 MAPK induced by a multicycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion
165. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats
166. Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart
167. Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death
168. The p38 signal transduction pathway activation and function
169. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion
170. Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts
171. Inhibition of p38 MAPK α/β reduces ischemic injury and does not block protective effects of preconditioning
172. Role of p38 MAP kinase in myocardial stress
173. Phosphorylation state of hsp27 and p38 MAPK during preconditioning and protein phosphatase inhibitor protection of rabbit cardiomyocytes
174. The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical
175. SB203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts
176. 203580 Is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1
177. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs)
178. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase
179. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitor SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase
180. Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580
181. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode
182. Ischemic preconditioning preserves creatine phosphate and intracellular pH
183. Effects of duration of ischaemia during preconditioning on mechanical function, enzyme release and energy production in the isolated working heart
184. Ischemic preconditioning stimulates anaerobic glycolysis in the isolated rabbit heart
185. Ischemic preconditioning inhibits glycolysis and proton production in isolated working rat hearts
186. Mechanisms of ischemic preconditioning in rat myocardium. Roles of adenosine, cellular energy state, and mitochondrial F1F0-ATPase
187. Ischemic preconditioning attenuates acidosis and postischemic dysfunction in isolated rat heart
188. Preconditioning in rat hearts is dependent of mitochondrial F1F0 ATPase inhibition
189. Effects of glycogen depletion on ischemic injury in isolated rat hearts: Insights into preconditioning
190. Paradoxical effect of ischemic preconditioning on ischemic contracture? NMR studies of energy metabolism and intracellular pH in the rat heart
191. Ischaemic preconditioning and contractile function: Studies with normothermic and hypothermic global ischaemia
192. A redox mechanism for cardioprotection induced by ischemic preconditioning in perfused rat heart
193. Effect of ischemic preconditioning on mitochondrial oxidative phosphorylation and high energy phosphates in rat hearts
194. Attenuated glycogenolysis reduces glycolytic catabolite accumulation during ischemia in preconditioning rat hearts
195. Ischemic preconditioning: A brief review
196. Loss of myocardial protection after preconditioning correlates with the time course of glycogen recovery within the preconditioned segment
197. Glycogen depletion contributes to ischemic preconditioning in the rat heart in vivo
198. Loss of glycogen during preconditioning is not a prerequisite for protection of the rabbit heart
199. + extrusion in preconditioned rat heart
200. Mechanism of preconditioning. Ionic alterations
201. Rapid adaptation of myocardial calcium homeostasis to short episodes of ischemia in isolated rat hearts
202. Intracellular free calcium and mitochondrial membrane potential in ischemia/reperfusion and preconditioning
203. ATP channels
204. Structure and physiology of calpain, an enigmatic protease
205. Role of troponin I proteolysis in the pathogenesis of stunned myocardium
206. ATP channel activation on myocardial cationic and energetic status during ischemia and reperfusion: Role in cardioprotection
207. Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning
208. Cardioadaptation induced by cyclic ischemic preconditioning is mediated by translational regulation of de Novo protein synthesis
209. Ischemic but not pharmacological preconditioning requires protein synthesis
210. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels
211. The mitochondrial KATP channel as a receptor for potassium channel openers
212. Mitochondrial ATP-dependent potassium channels. Novel effectors of cardioprotection?
213. + channels. Possible mechanism of cardioprotection
214. + channels and myocardial preconditioning
215. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part I: Effects on cardiomyocytes, coronary flow and pancreatic β-cells
216. ATP channels
217. ATP channels in ischemic cardioprotection
218. ATP channels in cardioprotection
219. ATP channels in cardioprotection
220. ATP channels in preconditioning
221. ATP channels triggers cardioprotection. Are reactive oxygen species involved?
222. ATP channels triggers the preconditioned state by generating free radicals
223. +-ATPase modulates ischemic preconditioning
224. ATP channels
225. ATP channel blocker HMR 1883 does not abolish the benefit of ischemic preconditioning on myocardial infarct mass in anesthetized rabbits
226. ATP channels in ischemic preconditioning of the canine heart
227. Pharmacological plasticity of cardiac ATP-sensitive potassium channels toward diazoxid revealed by ADP
228. S-T segment voltage during sequential coronary occlusions is an unreliable marker of preconditioning
229. + channels in rabbit heart
230. ATP channels. Triggers or distal effectors of ischemic or pharmacological preconditioning?
231. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism
232. + channel for cardiac protection against ischemic injury is dependent on protein kinase C activity
233. ATP) channels
234. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs
235. ATP channel opening is important during index ischemia and following myocardial reperfusion in ischemic preconditioned rat hearts
236. ATP-sensitive potassium channel modulation of guinea pig ventricular action potential and contraction
237. Involvement of activation of ATP-dependent potassium channels in ischemic preconditioning in swine
238. Potassium channels in cardiac cells
239. Die intracelluläre überladung mit kalzium als entscheidender kausalfaktor bei der entstehung nicht-coronarogener myokard-nekrosen
240. + blocker dofetilide
241. + channel of heart mitochondria
242. ATP in the heart - What happens, and what does not happen
243. + exchanger is critical to reperfusion damage and preconditioning in the isolated rat heart
244. The mechanism of protection from 5(N-ethyl-N-isopropyl)amiloride differs from that of ischemic preconditioning in rabbit heart
245. + exchanger
246. Adenosine A(1) receptor stimulation inhibits alpha(1)-adrenergic activation of the cardiac sarcolemmal Na(+)/H(+) exchanger
247. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion
248. + exchange mediated cardioprotection
249. + exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs
250. + exchanger isoforms (NHE-1, -2, and -3) are differentially responsive to second messenger agonists of the protein kinase A and C pathways
251. + exchange inhibition versus ischemic preconditioning
252. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27
253. Identification of MAPKAP kinase 2 as a major enzyme responsible for the phosphorylation of the small mammalian heat shock proteins
254. A comparison of the substrate specificity of MAPKAP kinase-2 and MAPKAP kinase-3 and their activation by cytokines and cellular stress
255. Small heat shock proteins are molecular chaperones
256. Small heat shock proteins and protection against ischemic injury in cardiac myocytes
257. HSP27 phosphorylation-mediated resistance against actin fragmentation and cell death induced by oxidative stress
258. Ischaemia and the myocyte cytoskeleton: Review and speculation
259. Ischemic preconditioning: A potential role for constitutive low molecular weight stress protein translocation and phosphorylation?
260. Translocation of HSP27 to sacromere induced by ischemic preconditioning in isolated rat hearts
261. 23Na NMR Study
262. Sarcolemmal blebs and osmotic fragility as correlates of irreversible ischemic injury in preconditioned isolated rabbit cardiomyocytes
263. Opening of potassium channels. The common cardioprotective link between preconditioning and natural hibernation?
264. Dissociation between anti-infarct effect and anti-edema effect of ischemic preconditioning
265. Chloride channel inhibition blocks the protection of ischemic preconditioning and hypo-osmotic stress in rabbit ventricular myocardium
266. No confirmation for a causal role of volume-regulated chloride channels in ischemic preconditioning in rabbits
267. Taurine depletion, a novel mechanism for cardioprotection from regional ischemia
268. 3 agonist reduces ischemic myocardial injury
269. Gap junctions in cardiovascular disease
270. Physiological role of gap-junctional hemichannels. Extracellular calcium-dependent isosmotic volume regulation
271. Heterogeneous loss of connexin 43 protein in ischemic dog hearts
272. Downregulation of immunodetectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle
273. Downregulation of connexin 43 gene expression in rat heart during inflammation. The role of tumor necrosis factor
274. p38 MAPK inhibition decreases TNF-α production and enhances postischemic human myocardial function
275. Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-α production. Potential ultimate effector mechanism of preconditioning
276. Endotoxin and ischemic preconditioning: TNF-α concentration and myocardial infarct development in rabbits
277. Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in acute myocardial infarction
278. The late phase of preconditioning
279. Delayed preconditioning of myocardium: Current perspectives
280. Characterisation of the infarct-limiting effect of delayed preconditioning: Time-course and dose-dependency studies in rabbit myocardium
281. The nitric oxide hypothesis of late preconditioning
282. Expression of second messenger- and cyclin-dependent protein kinases during postnatal development of rat heart
283. Expression of mitogen-activated protein kinase pathways during postnatal development of rat heart
284. The effect of age on cyclooxygenase-2 gene expression: NF-κB activation and IκBα degradation
285. Changes in ischemic tolerance and effect of ischemic preconditioning in middle-aged rat hearts
286. PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits
287. Both ischemic injury and preconditioning in mice are strain dependent
288. Resistance to myocardial ischemia in five rat strains: Is there a genetic component of cardioprotection?
289. Mitogen-activated protein kinases: Specific messages from ubiquitous messengers
290. Functional proteomic analysis of protein kinase Cε signaling complexes in the normal heart and during cardioprotection